Amgen drops Repatha list price by 60% to improve access for Medicare patients

Amgen Inc. (NASDAQ:AMGN) will reduce the U.S. list price of cardiovascular disease and hyperlipidemia drug Repatha evolocumab by 60% to improve access for Medicare patients, bringing it in line with the current rebate offered to payers and PBMs. At a new list price of $5,850 annually, down from the current $14,520, the PCSK9 inhibitor's discount will be passed on to patients via reduced co-pays.

Amgen said the reduced price matches the current net price it has been offering health plans and PBMs for Repatha, resulting in agreements with payers that represent more than 65% of Repatha’s commercial revenue...